Qube Holdings has postponed its second court hearing for the $5.20-per-share takeover by Rubik Australia, awaiting key regulatory approvals. The company plans to proceed with shareholder meetings and intends to pay a fully franked special dividend if the scheme proceeds.
- Second court hearing delayed from 18 June to 7 July 2026
- Shareholder meetings scheduled for 16 June 2026
- Regulatory approvals from ACCC, FIRB, and NZ OIO still pending
- Board plans fully franked special dividend of $0.3465 per share
- Board unanimously recommends shareholder approval subject to conditions
Regulatory Approvals Hold Up Scheme Progress
Qube Holdings Limited (ASX:QUB) has pushed back the critical second court hearing for its acquisition scheme from 18 June to 7 July 2026. This delay comes as the company awaits outstanding regulatory clearances from the Australian Competition and Consumer Commission (ACCC), the Australian Foreign Investment Review Board (FIRB), and the New Zealand Overseas Investment Office (OIO). The ACCC’s Phase 1 determination deadline is 19 June, while the OIO's decision is expected by early July, both pivotal for the scheme's advancement.
Shareholder Meetings Proceed as Scheduled
Despite the delay in court proceedings, Qube is pressing ahead with its General Scheme Meeting for shareholders (excluding UniSuper) on 16 June 2026, with the UniSuper Scheme Meeting to follow immediately. This move signals Qube’s intent to maintain momentum and keep shareholders engaged amid the regulatory wait. The revised timetable now anticipates the scheme becoming effective on 8 July, with implementation set for 14 August.
Special Dividend on the Horizon
Following the scheme’s anticipated effectiveness, the Qube Board intends to declare a fully franked special dividend of $0.3465 per share, as previously flagged. While the declaration remains at the board’s discretion, the special dividend aims to return value to shareholders ahead of the acquisition’s completion. The dividend record and payment dates are scheduled for 14 and 23 July respectively.
Board Endorses Scheme Subject to Conditions
The Qube Board continues to unanimously recommend that shareholders vote in favour of the scheme, provided no superior proposal emerges and the independent expert maintains its positive assessment. Board members have committed to voting their own shares in favour, reinforcing their confidence in the transaction. This endorsement is critical for shareholder confidence as the company navigates the final regulatory hurdles.
Bottom Line?
Regulatory approvals remain the key gating factor for Qube’s acquisition scheme, with shareholder meetings underway but court approval now delayed into July.
Questions in the middle?
- Will the ACCC and NZ OIO clear the scheme without conditions?
- Could a superior proposal emerge during the extended timeline?
- How will the special dividend impact shareholder sentiment ahead of the scheme’s implementation?